Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis

Shahjahani, Mohammad; Mohammadi-Asl, Javad; Noroozi, Fatemeh; Seghatoleslami, Mohammad; Shahrabi, Saeid; Saba, Fakhredin; Saki, Najmaldin

doi:10.1007/s13402-014-0215-3

Cited by 34 publications

(30 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CLL is the most common leukemia in middle age and is associated with abnormal proliferation of lymphocytes and their resistance to apoptosis [96]. About 60-65 % of CLL cases bear mutation in variable region of the immunoglobulin heavy chain (IGHV), which may change the affinity of B-cell receptor (BCR) for antigens.…”

Section: Chronic Lymphocytic Leukemia (Cll)mentioning

confidence: 99%

“…Twist-2 promoter in CLL patients with mutated IGHV (associated with favorable prognosis) is largely methylated, which results in silencing of TWIST-2 genes in these patients, while Twist2 is expressed in unmutated subtypes [96,100]. Some studies suggest that the expression of Twist-2 in unmutated IGHV patients with unmethylated Twist-2 can interfere with P53 pathway, but it has not been proved yet.…”

Section: Chronic Lymphocytic Leukemia (Cll)mentioning

confidence: 99%

See 1 more Smart Citation

Twist as a new prognostic marker in hematological malignancies

et al. 2015

View full text Add to dashboard Cite

Twist proteins are members of basic helix-loop-helix family and are major regulators of embryogenesis. In adult humans, Twist proteins are mainly expressed in precursor cells, including myogenic, osteoblastic, chondroblastic and myelomonocytic lineages, maintaining their undifferentiated state. In addition, they play important roles in lymphocyte function and maturation. Recently, several studies have reported regulatory roles for Twist in the function and development of hematopoietic cells as well as in survival and development of numerous hematological malignancies. It is activated by numerous signal transduction pathways, including Akt, nuclear factor κB, Wnt, signal transducer and activator of transcription 3, mitogen-activated protein kinase and Ras signaling. Activated Twist has an anti-apoptotic role and protects cancer cells from apoptotic cell death. In addition, overexpression of Twist promotes the process of epithelial-mesenchymal transition, which has an essential role in cancer metastasis. Hereby, we review the aberrant expression of Twist in hematopoietic malignancies such as leukemias, lymphomas and myelodysplastic syndrome, which is related with poor prognosis and drug resistance in these disorders. Inactivation of Twist by small RNAs technology or chemotherapeutic inhibitors targeting Twist and upstream or downstream molecules of Twist signaling pathways may be helpful in management of disease to improve treatment strategies in malignancies.

show abstract

Section: Chronic Lymphocytic Leukemia (Cll)mentioning

confidence: 99%

Section: Chronic Lymphocytic Leukemia (Cll)mentioning

confidence: 99%

Twist as a new prognostic marker in hematological malignancies

et al. 2015

View full text Add to dashboard Cite

show abstract

“…SmIgdim, CD5+, CD19+, CD20dim, CD23+) in peripheral blood, bone marrow, lymph nodes and other lymphoid tissues (Hodgson et al, 2011;Shahjahani et al, 2015). It is a heterogeneous disease with a variable clinical outcome (Mozaheb et al, 2012;.…”

Section: Introductionmentioning

confidence: 99%

Direct Coombs Test Positivity in B-Chronic Lymphoid Leukemia: a Marker of Advanced Clinical Disease

Abbas

Zeeshan²,

Sultan³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Imatinib, a first generation TKI, is a 2-phenylamiropyrimidine (PAP) derivative that competitively blocks the adenosine triphosphate (ATP) binding site of the BCR-ABL fusion protein, thereby preventing ATP from interacting with its catalytic domain [152]. This inhibitory activity impairs BCR-ABL auto-phosphorylation and its downstream signaling, leading to reduced proliferation and apoptosis-mediated cell death.…”

Section: Targeting Leukemia Stem Cellsmentioning

confidence: 99%

Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer

et al. 2016

View full text Add to dashboard Cite

Background Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are characterized by high self-renewal and multi-lineage differentiation capacities. CSCs are thought to play indispensable roles in the initiation, progression and metastasis of many types of cancer. Leukemias are thought to be initiated and maintained by a specific sub-type of CSC, the leukemia stem cell (LSC). An important feature of LSCs is their resistance to standard therapy, which may lead to relapse. Increasing efforts are aimed at developing novel therapeutic strategies that selectively target LSCs, while sparing their normal counterparts and, thus, minimizing adverse treatment-associated side-effects. These LSC targeting therapies aim to eradicate LSCs through affecting mechanisms that control their survival, self-renewal, differentiation, proliferation and cell cycle progression. Some LSC targeting therapies have already been proven successful in pre-clinical studies and they are now being tested in clinical studies, mainly in combination with conventional treatment regimens. Conclusions A growing body of evidence indicates that the selective targeting of LSCs represents a promising approach to improve disease outcome. Beyond doubt, the CSC hypothesis has added a new dimension to the area of anticancer research, thereby paving the way for shaping a new trend in cancer therapy.

show abstract

Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis

Cited by 34 publications

References 169 publications

Twist as a new prognostic marker in hematological malignancies

Twist as a new prognostic marker in hematological malignancies

Direct Coombs Test Positivity in B-Chronic Lymphoid Leukemia: a Marker of Advanced Clinical Disease

Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer

Contact Info

Product

Resources

About